4.7 Article

Rev-erb-α regulates atrophy-related genes to control skeletal muscle mass

期刊

SCIENTIFIC REPORTS
卷 7, 期 -, 页码 -

出版社

NATURE PUBLISHING GROUP
DOI: 10.1038/s41598-017-14596-2

关键词

-

资金

  1. INSERM
  2. Contrat Plan Etat Region (CPER)
  3. Region Nord Pas-de-Calais/FEDER
  4. EU consortium Eurhythdia (FP7)
  5. ANR-Labex-EGID (EGID) [ANR-10-LABX-46]
  6. EFSD (European Foundation for the Study of Diabetes)-Eli Lilly
  7. Fondation Francophone pour la recherche sur le diabete (FFRD)
  8. Federation Francaise des Diabetiques (AFD)
  9. AstraZeneca
  10. Eli Lilly
  11. Merck Sharp Dohme (MSD)
  12. Novo Nordisk
  13. Sanofi
  14. 'ERC-Region Hauts de France' grant
  15. Fondation de France
  16. Association Francaise contre les Myopathies (AFM)

向作者/读者索取更多资源

The nuclear receptor Rev-erb-alpha modulates hepatic lipid and glucose metabolism, adipogenesis and thermogenesis. We have previously demonstrated that Rev-erb-alpha is also an important regulator of skeletal muscle mitochondrial biogenesis and function, and autophagy. As such, Rev-erb-alpha overexpression in skeletal muscle or its pharmacological activation improved mitochondrial respiration and enhanced exercise capacity. Here, in gain-and loss-of function studies, we show that Rev-erb-alpha also controls muscle mass. Rev-erb-alpha-deficiency in skeletal muscle leads to increased expression of the atrophy-related genes (atrogenes), associated with reduced muscle mass and decreased fiber size. By contrast, in vivo and in vitro Rev-erb-alpha over-expression results in reduced atrogenes expression and increased fiber size. Finally, Rev-erb-alpha pharmacological activation blocks dexamethasone-induced upregulation of atrogenes and muscle atrophy. This study identifies Rev-erb-alpha as a promising pharmacological target to preserve muscle mass.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据